Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin

Journal of Clinical Microbiology

Volumn 44, Issue 1, 2006, Pages 151-159

  Kirkham, Lea Ann S ^a   Jefferies, Johanna M C ^a   Kerr, Alison R ^a   Jing, Yu ^a   Clarke, Stuart C ^a,b   Smith, Andrew ^c   Mitchell, Tim J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

^c GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN;

ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; EUROPE; GENE MUTATION; GENOTYPE; NONHUMAN; NORTH AMERICA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PNEUMOLYSIN GENE; POROSITY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; MICE; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

EID: 30744464885     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.44.1.151-159.2006     Document Type: Article

References (74)

1. Alexander, J. E., R. A. Lock, C. C. A. M. Peeters, J. T. Poolman, P. W. Andrew, T. J. Mitchell, D. Hansman, and J. C. Paton. 1994. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumonias. Infect. Immun. 62:5683-5688.
2. Alpern, E. R., E. A. Alessandrini, K. L. McGowan, L. M. Bell, and K. N. Shaw. 2001. Serotype prevalence of occult pneumococcal bacteremia. Pediatrics 108:E23.
3. Benton, K. A., M. P. Everson, and D. E. Briles. 1995. A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect. Immun. 63:448-455.
4. Benton, K. A., J. C. Paton, and D. E. Briles. 1997. The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model. Microb. Pathog. 23:201-209.
5. Berry, A. M., J. E. Alexander, T. J. Mitchell, P. W. Andrew, D. Hansman, and J. C. Paton. 1995. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect. Immun. 63:1969-1974.
6. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, K. Edwards et al. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195.
7. Bradford, M. M. 1976. A rapid and sensitive method for the quantisation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
8. 2 mediate brain cell apoptosis during meningitis. J. Clin. Investig. 109:19-27.
9. Briles, D. E., S. K. Hollingshead, G. S. Nabors, J. C. Paton, and A. Brooks-Walter. 2001. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19(Suppl. 1):S87-S95.
10. Brueggemann, A. B., D. T. Griffiths, E. Meats, T. Peto, D. W. Crook, and B. G. Spratt. 2003. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J. Infect. Dis. 187:1424-1432.
11. Brueggemann, A. B., and B. G. Spratt. 2003. Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates. J. Clin. Microbiol. 41:4966-4970.
12. Cima-Cabal, M. D., F. J. Mendez, F. Vazquez, M. del Mar Garcia-Suarez, and J. R. de los Toyos. 2001. A specific and ultrasensitive chemiluminescent sandwich ELISA test for the detection and quantitation of pneumolysin. J. Immunoassay Immunochem. 22:99-112.
13. Cockeran, R., R. Anderson, and C. Feldman. 2002. The role of pneumolysin in the pathogenesis of Streptococcus pneumoniae infection. Curr. Opin. Infect. Dis. 15:235-239.
14. Dagan, R., S. Gradstein, I. Belmaker, N. Porat, Y. Siton, G. Weber, J. Janco, and P. Yagupsky. 2000. An outbreak of Streptococcus pneumoniae serotype 1 in a closed community in southern Israel. Clin. Infect. Dis. 30:319-321.
15. de los Toyos, J. R., F. J. Méndez, J. F. Aparicio, F. Vázquez, M. del Mar Garcia Suárez, A. Fleites, C. Hardisson, P. J. Morgan, P. W. Andrew, and T. J. Mitchell. 1996. Functional analysis of pneumolysin by use of monoclonal antibodies. Infect. Immun. 64:480-484.
16. DeMaria, A., K. Browne, S. L. Berk, E. J. Sherwood, and W. R. McCabe. 1980. An outbreak of type 1 pneumococcal pneumonia in a men's shelter. JAMA 244:1446-1449.
17. Denham, B. C., and S. C. Clarke. 2005. Serotype incidence and antibiotic susceptibility of Streptococcus pneumoniae causing invasive disease in Scotland, 1999-2002. J. Med. Microbiol. 54:327-331.
18. Dochez, A. R., and L. J. Gillespie. 1913. A biologic classification of pneumococci by means of immunity reactions. Am. Med. Assoc. 6:727-732.
19. Eltringham, G., A. Kearns, R. Freeman, J. Clark, D. Spencer, K. Eastham, J. Harwood, and J. Leeming. 2003. Culture-negative childhood empyema is usually due to penicillin-sensitive Streptococcus pneumoniae capsular serotype 1. J. Clin. Microbiol. 41:521-522. (Letter.)
20. Enright, M. C., and B. G. Spratt. 1998. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144:3049-3060.
21. Feikin, D. R., and K. P. Klugman. 2002. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35:547-555.
22. Friedland, I. R., M. M. Paris, S. Hickey, S. Shelton, K. Olsen, J. C. Paton, and G. H. McCracken. 1995. The limited role of pneumolysin in the pathogenesis of pneumococcal meningilis. J. Infect. Dis. 172:805-809.
23. Gilbert, R. J. 2002. Pore-forming toxins. Cell Mol. Life Sci. 59:832-844.
24. Gratten, M., F. Morey, J. Dixon, K. Manning, P. Torzillo, R. Matters, J. Erlich, J. Hanna, V. Asche, and I. Riley. 1993. An outbreak of serotype 1 Streptococcus pneumoniae infection in central Australia. Med. J. Aust. 158:340-342.
25. Hausdorff, W. P., J. Bryant, P. R. Paradiso, and G. R. Siber. 2000. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30:100-121.
26. Hausdorff, W. P., J. Bryant, C. Kloek, P. R. Paradiso, and G. R. Siber. 2000. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin. Infect. Dis. 30:122-140.
27. Henrichsen, J. 1995. Six newly recognized types of Streptococcus pneumoniae. J. Clin. Microbiol. 33:2759-2762.
28. Henriques Normark, B., M. Kalin, A. Ortqvist, T. Akerlund, B. O. Liljequist, J. Hedlund, S. B. Svenson, J. Zhou, B. G. Spratt, S. Normark, and G. Kallenius. 2001. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J. Infect. Dis. 184:861-869.
29. Hotze, E. M., E. M. Wilson-Kubalek, J. Rossjohn, M. Parker, A. E. Johnson, and R. K. Tweten. 2001. Arresting pore formation of a cholesterol-dependent cytolysin by disulphide trapping synchronizes the insertion of the transmembrane β-sheet from a prepore intermediate. J. Biol. Chem. 276:8261-8266.
30. Ispahani, P., R. C. Slack, F. E. Donald, V. C. Weston, and N. Rutter. 2004. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Arch. Dis. Child. 89:757-762.
31. Jacobs, T., M. D. Cima-Cabal, A. Darji, F. J. Mendez, F. Vazquez, A. A. Jacobs, Y. Shimada, Y. Ohno-Iwashita, S. Weiss, and J. R. de los Toyos. 1999. The conserved undecapeptide shared by thiol-activated cytolysins is involved in membrane binding. FEBS Lett. 459:463-466.
32. Jefferies, J. M. C., A. Smith, S. C. Clarke, C. Dowson, and T. J. Mitchell. 2004. Genetic analysis of diverse disease-causing pneumococci indicates high levels of diversity within serotypes and capsule switching. J. Clin. Microbiol. 42:5681-5688.
33. Kalin, M., K. Kanclerski, M. Granstrom, and R. Möllby. 1987. Diagnosis of pneumococcal pneumonia by enzyme-linked immunosorbent assay of antibodies to pneumococcal hemolysin (pneumolysin). J. Clin. Microbiol. 25:226-229.
34. Kaplan, S. L., E. O. Mason, Jr., E. R. Wald, G. E. Schutze, J. S. Bradley, T. Q. Tan, J. A. Hoffman, L. B. Givner, R. Yogev, and W. J. Barson. 2004. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113:443-449.
35. Kerr, A. R., J. J. Irvine, J. J. Search, N. A. Gingles, A. Kadioglu, P. W. Andrew, W. L. McPheat, C. G. Booth, and T. J. Mitchell. 2002. Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection. Infect. Immun. 70:1547-1557.
36. Kipli, T., J. Jokinen, E. Herva, A. Palmu, S. Lockhart, G. Siber, J. Eskola et al. 2000. Effect of a heptavalent pneumococcal vaccine (PNCCRM) on pneumococcal acute otitis media (AOM) by serotype. Presented at the Second International Symposium on Pneumococci and Pneumococcal Disease, Sun City, South Africa, 19 to 23 March 2000, abstr. O20.
37. Klein, D. L. 1995. Pneumococcal conjugate vaccines: review and update. Microb. Drug Resist. 1:49-58.
38. Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. Mbelle, N. Pierce et al. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348.
39. Konradsen, H. B., and M. S. Kaltoft. 2002. Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance. Clin. Diagn. Lab. Immunol. 9:358-365.
40. Korchev, Y. E., C. L. Bashford, C. Pederzolli, C. A. Pasternak, P. J. Morgan, P. W. Andrew, and T. J. Mitchell. 1998. A conserved tryptophan in pneumolysin is a determinant of the characteristics of channels formed by pneumolysin in cells and planar lipid bilayers. Biochem. J. 329:571-577.
41. Kostyukova, N. N., M. O. Volkova, V. V. Ivanova, and A. S. Kvetnaya. 1995. A study of pathogenic factors of Streptococcus pneumoniae strains causing meningitis. FEMS Immunol. Med. Microbiol. 10:133-137.
42. Kuo, J., M. Douglas, H. K. Ree, and A. A. Lindberg. 1995. Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines. Infect. Immun. 63:2706-2713.
43. Kyaw, M. H., P. Christie, S. C. Clarke, J. D. Mooney, S. Ahmed, I. G. Jones, and H. Campbell. 2003. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin. Infect. Dis. 37:1283-1291.
44. Leimkugel, J., A. Adams Forgor, S. Gagneux, V. Pfluger, C. Flierl, E. Awine, M. Naegeli, J. P. Dangy, T. Smith, A. Hodgson, and G. Pluschke. 2005. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J. Infect. Dis. 192:192-199.
45. Lock, R. A., Q. Y. Zhang, A. M. Berry, and J. C. Paton. 1996. Sequence variation in the Streptococcus pneumoniae pneumolysin gene affecting haemolytic activity and electrophoretic mobility of the toxin. Microb. Pathog. 21:71-83.
46. Malley, R., P. Henneke, S. C. Morse, M. J. Cieslewicz, M. Lipsitch, C. M. Thompson, E. Kurt-Jones, J. C. Paton, M. R. Wessels, and D. T. Golenbock. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. USA 100:1966-1971.
47. Martens, P., S. W. Worm, B. Lundgren, H. B. Konradsen, and T. Benfield. 30 June 2004, posting date. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect. Dis. 4:21. [Online.] doi:10.1186/1471-2334-4-21.
48. McChlery, S. M., K. J. Scott, and S. C. Clarke. 2005. Clonal analysis of invasive pneumococcal isolates in Scotland and coverage of serotypes by the licensed conjugate polysaccharide pneumococcal vaccine: possible implications for UK vaccine policy. Eur. J. Clin. Microbiol. Infect. Dis. 24:262-267.
49. McFarlane, A. C., L. K. Hamra, E. Reiss-Levy, and D. Hansman. 1979. Pneumococcal peritonitis in adolescent girls. Med. J. Aust. 1:100-101.
50. Mercat, A., J. Nguyen, and B. Dautzenberg. 1991. An outbreak of pneumococcal pneumonia in two men's shelters. Chest 99:147-151.
51. Michon, F., P. C. Fusco, C. A. S. A. Minetti, M. Laude-Sharp, C. Uitz, C.-H. Huang, A. J. D'Ambra, S. Moore, D. P. Remeta, I. Heron, and M. S. Blake. 1998. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein. Vaccine 16:1732-1741.
52. Mitchell, T. J., and P. W. Andrew. 1997. Biological properties of pneumolysin. Microb. Drug Resist. 3:19-26.
53. Mitchell, T. J., F. Mendez, J. C. Paton, P. W. Andrew, and G. J. Boulnois. 1990. Comparison of pneumolysin genes and proteins from Streptococcus pneumoniae types 1 and 2. Nucleic Acids Res. 18:4010.
54. Mitchell, T. J., J. A. Walker, F. K. Saunders, P. W. Andrew, and G. J. Boulnois. 1989. Expression of the pneumolysin gene in Escherichia coli: rapid purification and biological properties. Biochim. Biophys. Acta 1007:67-72.
55. Nurkka, A., J. Joensuu, I. Henckaerts, P. Peeters, J. Poolman, T. Kilpi, and H. Kayhty. 2004. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr. Infect. Dis. J. 23:1008-1014.
56. Ogunniyi, A. D., M. C. Woodrow, J. T. Poolman, and J. C. Paton. 2001. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect. Immun. 69:5997-6003.
57. Owen, R. H., G. J. Boulnois, P. W. Andrew, and T. J. Mitchell. 1994. A role in cell-binding for the C-terminus of pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae. FEMS Microbiol. Lett. 121:217-221.
58. Palmer, M. 2001. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 39:1681-1689.
59. Paton, J. C., R. A. Lock, and D. J. Hansman. 1983. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect. Immun. 40:548-552.
60. Ramachandran, R., A. P. Heuck, R. K. Tweten, and A. E. Johnson. 2002. Structural insights into the membrane-anchoring mechanism of a cholesterol-dependent cytolysin. Nat. Struct. Biol. 9:823-827.
61. Ramachandran, R., R. K. Tweten, and A. E. Johnson. 2004. Membrane-dependent conformational changes initiate cholesterol-dependent cytolysin oligomerization and intersubunit-strand alignment. Nat. Struct. Mol. Biol. 11:697-705.
62. Rubins, J., D. Charboneau, C. Fasching, A. Berry, J. Paton, J. Alexander, P. Andrew, T. Mitchell, and E. Janoff. 1996. Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia. Am. J. Respir. Crit. Care Med. 153:1339-1346.
63. Rubins, J. B., D. Charboneau, J. C. Paton, T. J. Mitchell, P. W. Andrew, and E. N. Janoff. 1995. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J. Clin. Investig. 95:142-150.
64. Sandgren, A., K. Sjostrom, B. Olsson-Liljequist, B. Christensson, A. Samuelsson, G. Kronvall, and B. Henriques Normark. 2004. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J. Infect. Dis. 189:785-796.
65. Sirotnak, A. P., S. C. Eppes, and J. D. Klein. 1996. Tuboovarian abscess and peritonitis caused by Streptococcus pneumoniae serotype 1 in young girls. Clin. Infect. Dis. 22:993-996.
66. Tan, T. Q., E. O. Mason, Jr., E. R. Wald, W. J. Barson, G. E. Schutze, J. S. Bradley, L. B. Givner, R. Yogev, K. S. Kim, and S. L. Kaplan. 2002. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics 110:1-6.
67. Tweten, R. K., M. W. Parker, and A. E. Johnson. 2001. The cholesterol-dependent cytolysins. Curr. Top. Microbiol. Immunol. 257:15-33.
68. Walker, J. A., R. L. Allen, P. Falmagne, M. K. Johnson, and G. J. Boulnois. 1987. Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae. Infect. Immun. 55:1184-1189.
69. Wash, M. O., G. Pimentel, M. Abdel-Maksoud, K. L. Russell, C. P. Barrozo, J. D. Klena, K. Earhart, and R. Hajjeh. 2005. Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998-2003. J. Antimicrob. Chemother. 55:958-964.
70. Wellmer, A., G. Zysk, J. Gerber, T. Kunst, M. von Mering, S. Bunkowski, H. Eiffert, and R. Nau. 2002. Decreased virulence of a pneumolysin-deficient strain of Streptococcus pneumoniae in murine meningitis. Infect. Immun. 70:6504-6508.
71. Wessels, M. R., P. Butko, M. Ma, H. B. Warren, A. L. Lage, and M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92:11490-11494.
72. Westh, H., L. Skibsted, and B. Korner. 1990. Streptococcus pneumoniae infections of the female genital tract and in the newborn child. Rev. Infect. Dis. 12:416-422.
73. Whitney, C. G., M. M. Farely, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, and A. Schuchat. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.
74. Winter, A. J., S. D. Comis, M. P. Osborne, M. J. Tarlow, J. Stephen, P. W. Andrew, J. Hill, and T. J. Mitchell. 1997. A role for pneumolysin hut not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs. Infect. Immun. 65:4411-4418.